D2C7 immunotoxin
- Generic Name
- D2C7 immunotoxin
- Drug Type
- Biotech
- Background
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
D2C7-IT + 2141-V11 Combination Post-resection in RGBM
- Conditions
- Recurrent Glioblastoma IDH Wildtype
- Interventions
- Drug: 2141 V11
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Darell Bigner
- Target Recruit Count
- 46
- Registration Number
- NCT06455605
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
- Conditions
- Newly Diagnosed MGMT Unmethylated Glioblastoma
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Darell Bigner
- Target Recruit Count
- 50
- Registration Number
- NCT05734560
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Darell Bigner
- Target Recruit Count
- 90
- Registration Number
- NCT04547777
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
D2C7-IT With Atezolizumab for Recurrent Gliomas
- Conditions
- Malignant Glioma
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Darell Bigner
- Target Recruit Count
- 18
- Registration Number
- NCT04160494
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
D2C7 for Adult Patients With Recurrent Malignant Glioma
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Darell Bigner
- Target Recruit Count
- 81
- Registration Number
- NCT02303678
- Locations
- 🇺🇸
Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.